BALAXI PHARMACEUTICALS LIMITED

400 billion

J, Republic \« é. Ecuador Zambia K- I Nee Balaxi Existing/targeted markets have aggregate GDP of S 400 billion and pharma imports of $6 billion ~~~ aiax! Key Milestones Started business supplying white labelled

6 billion

- I Nee Balaxi Existing/targeted markets have aggregate GDP of S 400 billion and pharma imports of $6 billion ~~~ aiax! Key Milestones Started business supplying white labelled products to customers in Africa

INR 49.36 crore

Central African Republic Successfully completed fund raising exercise through Preferential issue — INR 49.36 crore Robust capex plans — Project initiated for EU-GMP. compliant manufacturing plant in ‘ee ps Balaxi B

40%

e Latin American markets — Guatemala, Honduras and El Salvador. These LATM markets have contributed 40% of our pharmaceuticals revenues and we are confident of increasing this further as we penetrate the

60%

es. Our mature presence in Angola has also contributed with another steady performance contributing 60% of the pharmaceuticals business. As on 31 December, the number of registered products in our portfo

19.7%

ary of Balaxi Global DMCC with effect from 1* January 2022 Balaxi Q3FY22 61.72 yy COR 13.55 OY any) 19.7% a} ro) 1 sn]: SPR VAIS CEmcy 20.5% 34.94 18.5% Byles Pharma Product Mix — Q3 FY23 Geographies = Ang

20.5%

ct from 1* January 2022 Balaxi Q3FY22 61.72 yy COR 13.55 OY any) 19.7% a} ro) 1 sn]: SPR VAIS CEmcy 20.5% 34.94 18.5% Byles Pharma Product Mix — Q3 FY23 Geographies = Angola = LATM* Products = Branded m= G

18.5%

anuary 2022 Balaxi Q3FY22 61.72 yy COR 13.55 OY any) 19.7% a} ro) 1 sn]: SPR VAIS CEmcy 20.5% 34.94 18.5% Byles Pharma Product Mix — Q3 FY23 Geographies = Angola = LATM* Products = Branded m= Generics Dosa

5%

= Others *LATM — Guatemala, Dominican Republic, Hondurus and El Salvador Balaxi Therapeutic Areas 4 5% # Antibiotics = Analgesic m Anti-malaria = Others ‘Quarterly Performance Commentary Balaxi Revenue

40.3%

ntary Balaxi Revenue = Higher contribution from the pharmaceuticals business led to y-o-y growth of 40.3% in revenues for Q3 FY23 compared to corresponding quarter last year. The share of LATM markets incr

Rs. 15.3 crore

ed for expanding into new markets. Operating EBITDA = During the quarter, operating EBITDA stood at Rs. 15.3 crore, a growth of 12.8% y-o-y. This was on account of increasing contribution from LATM markets and expa

12.8%

rkets. Operating EBITDA = During the quarter, operating EBITDA stood at Rs. 15.3 crore, a growth of 12.8% y-o-y. This was on account of increasing contribution from LATM markets and expansion into newer ge